QuickView for pha 767491 (compound)

1. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
2. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
3. L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
4. L1000 CMAP - Neural progenitor NPC.CAS9 cells treated with small molecule perturbagens
5. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)

1. Targeting Inflammation, PHA-767491 Shows a Broad Spectrum in Protein Aggregation Diseases.
2. Antiviral activity of PHA767491 against human herpes simplex virus in vitro and in vivo.
3. Dbf4-Cdc7 (DDK) Inhibitor PHA-767491 Displays Potent Anti-Proliferative Effects via Crosstalk with t…
4. Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegra…
5. Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activat…

There were no clinical trials for pha 767491